阿斯利康(AZN.US)宣布PD-L1单抗在华获批新适应症针对子宫内膜癌

智通财经01-23

智通财经APP获悉，1月22日，阿斯利康(AZN.US)宣布，英飞凡®(英文商品名：IMFINZI®，通用名：度伐利尤单抗)已获中国国家药品监督管理局(NMPA)批准，与卡铂和紫杉醇联合用于错配修复缺陷(dMMR)的原发晚期或复发性子宫内膜癌成人患者的一线治疗，随后以本品单药维持治疗。度伐利尤单抗是一种人源化的PD-L1单克隆抗体，可与PD-L1蛋白结合，能够阻断PD-L1与PD-1和CD80蛋白...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2605290194?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-23 14:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605290194","market":"us","top_or_hot":-1,"title":"阿斯利康(AZN.US)宣布PD-L1单抗在华获批新适应症 针对子宫内膜癌","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，1月22日，阿斯利康(AZN.US)宣布，英飞凡®(英文商品名：IMFINZI®，通用名：度伐利尤单抗)已获中国国家药品监督管理局(NMPA)批准，与卡铂和紫杉醇联合用于错配修复缺陷(dMMR)的原发晚期或复发性子宫内膜癌成人患者的一线治疗，随后以本品单药维持治疗。度伐利尤单抗是一种人源化的PD-L1单克隆抗体，可与PD-L1蛋白结合，能够阻断PD-L1与PD-1和CD80蛋白...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1396591.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阿斯利康(AZN.US)宣布PD-L1单抗在华获批新适应症 针对子宫内膜癌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阿斯利康(AZN.US)宣布PD-L1单抗在华获批新适应症 针对子宫内膜癌\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-23 14:42 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1396591.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，1月22日，阿斯利康(AZN.US)宣布，英飞凡®(英文商品名：IMFINZI®，通用名：度伐利尤单抗)已获中国国家药品监督管理局(NMPA)批准，与卡铂和紫杉醇联合用于错配修复缺陷(dMMR)的原发晚期或复发性子宫内膜癌成人患者的一线治疗，随后以本品单药维持治疗。度伐利尤单抗是一种人源化的PD-L1单克隆抗体，可与PD-L1蛋白结合，能够阻断PD-L1与PD-1和CD80蛋白...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1396591.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2417539215.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1396591.html","article_id":"2605290194","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605290194","pubTimestamp":1769150545,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，1月22日，阿斯利康宣布，英飞凡已获中国国家药品监督管理局批准，与卡铂和紫杉醇联合用于错配修复缺陷的原发晚期或复发性子宫内膜癌成人患者的一线治疗，随后以本品单药维持治疗。截至目前该药已在美国获批 10 项适应症，在欧盟获批 11 项适应症，在国内获批 7 项。安全性方面，度伐利尤单抗联合化疗方案的总体安全性和耐受性良好，并且与此前临床试验结果总体一致，没有出现新的安全信号。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4007":"制药","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4568":"美国抗疫概念","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","AZN":"阿斯利康","BK4588":"碎股","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4585":"ETF&股票定投概念","BK4023":"应用软件","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","PD":"PagerDuty, Inc."},"translate_title":"AstraZeneca (AZN.US) announced that PD-L1 monoclonal antibody has been approved for new indications in China for endometrial cancer","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1.5,"PD":1.5},"content_text":"智通财经APP获悉，1月22日，阿斯利康(AZN.US)宣布，英飞凡®(英文商品名：IMFINZI®，通用名：度伐利尤单抗)已获中国国家药品监督管理局(NMPA)批准，与卡铂和紫杉醇联合用于错配修复缺陷(dMMR)的原发晚期或复发性子宫内膜癌成人患者的一线治疗，随后以本品单药维持治疗。度伐利尤单抗是一种人源化的PD-L1单克隆抗体，可与PD-L1蛋白结合，能够阻断PD-L1与PD-1和CD80蛋白的结合，从而阻断肿瘤免疫逃逸并恢复被抑制的免疫反应。截至目前该药已在美国获批 10 项适应症，在欧盟获批 11 项适应症，在国内获批 7 项。此次度伐利尤单抗在中国获批是基于DUO-E 3期试验中根据MMR状态预设的亚组分析结果。DUO-E 试验 (GOG 3041/ENGOT-EN10) 是一项三臂、随机、双盲、安慰剂对照、多中心3期试验，以一线度伐利尤单抗联合铂类化疗 (卡铂和紫杉醇)为基础治疗，随后以度伐利尤单抗单药或度伐利尤单抗联合奥拉帕利作为维持治疗，与单独使用铂类化疗相比，用于对于新诊断的晚期或复发性子宫内膜癌患者。在试验中，与卡铂联合紫杉醇治疗相比，度伐利尤单抗联合卡铂和紫杉醇治疗，随后进行度伐利尤单抗单药维持治疗可使dMMR子宫内膜癌患者的病情进展或死亡风险降低58%，度伐利尤单抗组的中位无疾病进展生存期(PFS)尚未达到，对照组的中位PFS为7.0个月。安全性方面，度伐利尤单抗联合化疗方案的总体安全性和耐受性良好，并且与此前临床试验结果总体一致，没有出现新的安全信号。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605290194","isCrawlerRequest":true}

阿斯利康(AZN.US)宣布PD-L1单抗在华获批新适应症 针对子宫内膜癌

精彩评论

阿斯利康(AZN.US)宣布PD-L1单抗在华获批新适应症针对子宫内膜癌